FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial.

ABSTRACT:

Background

The CANVAS (Canagliflozin Cardiovascular Assessment Study) trial provided the opportunity to determine the utility of measuring cardiorenal biomarkers, such as fibroblast growth factor 23 (FGF-23) and high-sensitivity C-reactive protein (hsCRP) levels for determining risk prediction and treatment response to sodium glucose co-transporter 2 inhibitor therapy in patients with type 2 diabetes mellitus.

Objectives

The prognostic value of these biomarkers for predicting adverse cardiovascular (CV) outcomes and treatment response was assessed.

Methods

Of 4,330, 3,188 (73.6%) participants had available longitudinal biomarker samples. The association between FGF-23 and hsCRP with composite CV death or hospitalization for heart failure (HHF), HHF, CV death, and majo

SUBMITTER: Punithan A 

PROVIDER: S-EPMC12596612 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature